Genflow Biosciences is advancing research into animal longevity after reporting positive results from a gene therapy trial involving older dogs.
The UK-based biotechnology company said its experimental treatment, GF-1002, reduced biological age measurements in older beagles, meeting the primary objective of its SLAB trial.
The treatment delivers a version of the SIRT6 gene, which is associated with DNA repair and metabolic regulation. Genflow is investigating its potential to address biological ageing and muscle loss.
The randomised, blinded study involved 24 beagles aged over 10 years, divided into groups receiving different doses and delivery methods of the treatment or a placebo. Biological age was assessed using the GRIM DNA methylation clock, with treated dogs recording lower measurements than untreated animals.
The company had previously reported positive interim muscle results, alongside improvements in functional measures. It also said safety and benefits were maintained at a three-month follow-up.
The findings come as biotechnology companies increase investment in treatments designed to extend the healthy lifespans of companion animals. Genflow is among the businesses developing gene-based approaches, with discussions reportedly taking place with animal health companies about potential commercial opportunities.
The full trial dataset is yet to be published in a peer-reviewed journal, and further evidence will be needed to establish the treatment’s longer-term benefits.
Genflow Biosciences plc (LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs supporting longer, healthier lives









































